ライフサイエンスコーパス: APBI

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 Therefore, adjuvant APBI using multicatheter brachytherapy after breast-cons

2 ne patient developed severe distortion after APBI, while two patients developed only mild distortion

3 the relative cytotoxicity of various PBI and APBI derivatives.

4 figuration of the 3-position of the PBIs and APBIs influence DT-diaphorase substrate activity to a le

5 phorase reductase activity for both PBIs and APBIs.

6 midopyrrolo[1,2-alpha]benzimidazolequinones (APBIs).

7 BI has little cytotoxicity while the 7-butyl APBI has enhanced cytotoxicity.

8 on support large randomized trials comparing APBI with standard whole-breast irradiation after breast

9 ed after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10 fractions twice daily) or WBI (42.5

10 3D-CRT APBI increased rates of adverse cosmesis and late radiat

11 2,135 women were randomly assigned to 3D-CRT APBI or WBI.

12 ents are cautioned against the use of 3D-CRT APBI outside the context of a controlled trial.

13 he interacalation of only electron deficient APBIs into DNA.

14 ve an overview of the biologic rationale for APBI techniques, and benefits and limitations of APBI te

15 imitations that suggest a potential role for APBI as a more user-friendly mode for delivering radioth

16 idinyl group (PBIs) and a 6-acetamido group (APBIs).

17 ial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cance

18 Accelerated partial-breast irradiation (APBI) involves treating a limited volume of breast tissu

19 n of accelerated partial-breast irradiation (APBI).

20 Patients treated with MammoSite APBI developed peak distortion 21 months following thera

21 techniques, and benefits and limitations of APBI techniques.

22 h 7-methoxy results in a substantial loss of APBI cytotoxicity as well as decreased topoisomerase II

23 Four currently available methods of APBI are interstitial brachytherapy, intracavitary brach

24 Several techniques of APBI are being investigated; however, most experience, a

25 instead of methyl) had an adverse effect on APBI inhibition of topoisomerase II while the configurat

26 iants of the pyrrolo[1, 2-a]benzimidazole or APBI ring system.

27 omised to either whole-breast irradiation or APBI using multicatheter brachytherapy.

28 t cancer; and currently accruing and planned APBI trials.

29 h tumour-bed boost and 633 patients received APBI using interstitial multicatheter brachytherapy.

30 ties were increased among those who received APBI compared with WBI (P < .001).

31 The APBIs are cytotoxic only as quinones, and reduction to t

32 ned to inhibit topoisomerase II, much as the APBIs are able to do.

33 Indeed, the APBIs possess a high inverse correlation with the cellul

34 Since only the quinone form of the APBIs can intercalate DNA, two-electron reduction to the

35 DNA via major groove interactions, while the APBIs are reductively inactivated by this enzyme since o

36 ree-dimensional conformal radiation therapy, APBI has very recently come to the forefront as a potent

37 2% with whole-breast irradiation and 0% with APBI (p=0.46).

38 late side-effects to the skin was 3.2% with APBI versus 5.7% with whole-breast irradiation (p=0.08),

39 recurrence was 1.44% (95% CI 0.51-2.38) with APBI and 0.92% (0.12-1.73) with whole-breast irradiation

40 ving approximately 500 patients treated with APBI after breast-conserving surgery have been published

41 5-year follow-up, nine patients treated with APBI and five patients receiving whole-breast irradiatio

42 years was increased among those treated with APBI compared with WBI as assessed by trained nurses (29

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。